Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993–2000.

Nakamura T, Takahashi T, Fukui M, et al.: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995, 5:1492–1497.

Remuzzi A, Fassi A, Bertani T, et al.: ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis. 1999, 34:626-32.

Remuzzi A, Gagliardini E, Donadoni C, et al.: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int. 2002, 62:885-94.

Remuzzi A, Gagliardini E, Sangalli F, et al.: ACE inhibition reduce glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006, 69:1124–1130.

Macconi D, Abbate M, Morigi M, et al.: Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 2006, 168:1073–1085.




Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1:1175–1179.

Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 1213:754–762.

The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857–1863.

Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448–1456.

Ruggenenti P, Perna A, Benini R, et al.: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999, 10:997–1006.

Ruggenenti P, Brenner BM, Remuzzi G: Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 2001, 88:254–259.

Gerstein HC, Mann JF, Yi Q, et al., for the HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.

Wachtell K, Ibsen H, Olsen MH, et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139:901–906.

Ruggenenti P, Fassi A, Ilieva AP, et al., for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.




Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448–1456.

Ruggenenti P Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001, 375:1601–1608.

Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288–296.

Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? Kidney Int 2006, 70:1214–1222.

Remuzzi G, Remuzzi A: Is regression of chronic nephropathies a therapeutic target? J Am Soc Nephrol. 2005, 16:840-2.

 
© 2009-2021 Mario Negri Istitute  - All Rights Reserved - Credits